Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF
V. Welk (Hallbergmoos, Germany), M. Pavlidou (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), S. Grüner (Hallbergmoos, Germany), J. Peper-Gabriel (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), A. Konitsiotis (Hallbergmoos, Germany), J. Morgenstern (Hallbergmoos, Germany), J. Prassler (Hallbergmoos, Germany), G. Matschiner (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany)
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Welk (Hallbergmoos, Germany), M. Pavlidou (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), S. Grüner (Hallbergmoos, Germany), J. Peper-Gabriel (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), A. Konitsiotis (Hallbergmoos, Germany), J. Morgenstern (Hallbergmoos, Germany), J. Prassler (Hallbergmoos, Germany), G. Matschiner (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany). Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPF. 732
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis Source: Eur Respir J 2006; 27: 460-469 Year: 2006
AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014